The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 25, 2025

Filed:

Dec. 06, 2019
Applicants:

Jiangsu Hengrui Medicine Co., Ltd., Jiangsu, CN;

Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai, CN;

Inventors:

Hua Ying, Shanghai, CN;

Ling Zhang, Shanghai, CN;

Xiaoying Yang, Shanghai, CN;

Hu Ge, Shanghai, CN;

Weikang Tao, Shanghai, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61P 35/00 (2006.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2809 (2013.01); A61P 35/00 (2018.01); C07K 16/2827 (2013.01); C07K 16/468 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present disclosure relates to a CD3 antibody and a pharmaceutical use thereof. Specifically, the present disclosure relates to forming a multi-specificity antibody by using CD3 antibody and binding molecules of another target. The multi-specificity antibody may simultaneously bind to CD3 and another tumor-associated antigen, and bind and activate CD3-positive T cells while binding tumor-associated antigen-expressing cells, thereby promoting T cells specifically killing tumor cells that express tumor-associated antigens. In addition, the present disclosure also provides a preparation and application of a multi-specific antibody.


Find Patent Forward Citations

Loading…